Rubicon Q1FY27: consolidated PAT up 96% YoY to ₹84.8 Cr, margin beats 22-23% guidance

Rubicon Research's consolidated print for the quarter ended June 30, 2026 came in well ahead of the revenue range flagged in our pre-result preview (₹350–370 Cr) at ₹534.3 Cr, though that preview range was already below the prior quarter's own ₹513.9 Cr base, so the comparison is of limited use. On margins, the preview's 32–35% EBITDA-margin expectation was not met — actual consolidated EBITDA margin works out to roughly 25.2% (standalone ~29.8%). We could not find a formal analyst consensus for this print (WebSearch turned up none, consistent with our own preview's note that coverage is thin and the stock trades on the growth/capital-deployment narrative rather than consensus earnings forecasts), so vsStreet is unknown. Against management's own guidance, the quarter is a clear beat: at the Q4FY26 call management reiterated an EBITDA margin band of 22–23% for coming quarters, factoring in ESOP costs, Arinna-related expenses and Pithampur ramp-up. Actual consolidated margin of ~25.2% (standalone ~29.8%) sits above that band. Consolidated NPM also expanded to 15.7%, from 14.9% in Q4FY26 and 12.3% a year ago, so the margin trend is expanding on both a sequential and annual basis. The mechanics behind the print are worth separating from the headline growth. Consolidated revenue (+51.6% YoY, +4.0% QoQ) and PAT (+95.8% YoY, +10.4% QoQ) both grew strongly, but consolidated PBT (₹110.4 Cr) was essentially flat versus standalone PBT (₹110.7 Cr) even though consolidated revenue is 25% higher — the four subsidiaries not independently reviewed by the parent's auditors (which include Arinna, consolidated only from April 30, 2026) contributed a combined ₹14.2 Cr net loss for the quarter, an integration drag that shows up below the revenue line. Consolidated PAT nonetheless finished above standalone PAT because of a lower group effective tax rate (23.2% vs 25.5% standalone) rather than because the new subsidiaries were profit-accretive this quarter. Corporate activity this quarter lines up with the pre-result thesis: the ₹175.9 Cr, 85%-stake Arinna Lifesciences acquisition completed April 30, 2026 and is now consolidated (with the caveat above); the board approved a Kia Health Tech amalgamation scheme on July 20, 2026 (filed with the RoC on August 3, 2026, not yet effective, so no P&L impact this quarter); and of the ₹471.3 Cr net IPO proceeds, ₹80.6 Cr remains unutilised as of June 30, 2026, with the deployment timeline extended to March 31, 2027. Post quarter-end, subsidiary AdvaGen Holdings acquired a US manufacturing facility in East Brunswick, New Jersey for USD 2.9 million, extending the US CDMO footprint flagged in the preview. No management press release was available in the extraction context to cross-check against their own framing of the quarter, so the numbers above are the primary signal on execution this period.